全文获取类型
收费全文 | 1181135篇 |
免费 | 318909篇 |
国内免费 | 43117篇 |
专业分类
耳鼻咽喉 | 16100篇 |
儿科学 | 29810篇 |
妇产科学 | 29075篇 |
基础医学 | 210593篇 |
口腔科学 | 29255篇 |
临床医学 | 140481篇 |
内科学 | 258744篇 |
皮肤病学 | 21862篇 |
神经病学 | 94741篇 |
特种医学 | 46460篇 |
外国民族医学 | 213篇 |
外科学 | 182300篇 |
综合类 | 87789篇 |
现状与发展 | 25篇 |
一般理论 | 284篇 |
预防医学 | 108761篇 |
眼科学 | 40053篇 |
药学 | 128531篇 |
59篇 | |
中国医学 | 52294篇 |
肿瘤学 | 65731篇 |
出版年
2019年 | 21187篇 |
2018年 | 24074篇 |
2017年 | 22642篇 |
2016年 | 21889篇 |
2015年 | 24347篇 |
2014年 | 28507篇 |
2013年 | 33621篇 |
2012年 | 41710篇 |
2011年 | 44907篇 |
2010年 | 34494篇 |
2009年 | 39764篇 |
2008年 | 38690篇 |
2007年 | 37770篇 |
2006年 | 37048篇 |
2005年 | 36901篇 |
2004年 | 36703篇 |
2003年 | 34621篇 |
2002年 | 33480篇 |
2001年 | 48179篇 |
2000年 | 44971篇 |
1999年 | 44214篇 |
1998年 | 22848篇 |
1997年 | 21796篇 |
1996年 | 22252篇 |
1995年 | 21875篇 |
1994年 | 21185篇 |
1993年 | 19289篇 |
1992年 | 38318篇 |
1991年 | 37046篇 |
1990年 | 35564篇 |
1989年 | 34420篇 |
1988年 | 32597篇 |
1987年 | 31613篇 |
1986年 | 29976篇 |
1985年 | 28382篇 |
1984年 | 21989篇 |
1983年 | 19598篇 |
1982年 | 15270篇 |
1981年 | 14187篇 |
1980年 | 13378篇 |
1979年 | 22331篇 |
1978年 | 16968篇 |
1977年 | 15285篇 |
1976年 | 14125篇 |
1975年 | 14685篇 |
1974年 | 16936篇 |
1973年 | 16173篇 |
1972年 | 15528篇 |
1971年 | 14152篇 |
1970年 | 13464篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
41.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
42.
目的 探讨不同年龄阿尔茨海默病(AD)患者ADC值与年龄的相关性。方法 选取30例AD患者(AD组)和年龄与之相匹配的30名志愿者(对照组),按年龄段各分为6个亚组[55~59岁(n=3)、60~64岁(n=4)、65~70岁(n=9)、71~74岁(n=5)、75~80岁(n=6)、>80岁(n=3)],测量双侧海马、红核、尾状核、杏仁体、壳核ADC值,并进行配对t检验、独立样本t检验、单因素方差分析及Pearson相关分析。结果 AD组红核左、右侧ADC值有统计学差异(P=0.022)。AD组不同年龄亚组右侧海马、双侧尾状核、右侧壳核ADC值差异有统计学意义(P均<0.05);2组不同年龄亚组双侧海马、壳核、尾状核ADC值差异有统计学意义(P均<0.05)。AD组右侧海马(r=0.615,P<0.001)、右侧壳核(r=0.653,P=0.001)及双侧尾状核(左侧:r=0.397,P=0.030;右侧:r=0.429,P=0.020)ADC值与年龄呈正相关。结论 AD患者右侧海马和壳核、双侧尾状核ADC值随年龄增加而增大。ADC值可为临床预测和早期诊断AD脑内右侧海马和壳核、双侧尾状核神经退行性病变提供参考。 相似文献
43.
44.
45.
良性前列腺增生(BPH)是老年男性常见的泌尿系统疾病,其发病与前列腺慢性炎症之间存在显著相关。感染因子、尿液返流、代谢综合征、衰老过程和自身免疫应答在内的几种刺激,通过相应分子途径引起前列腺免疫细胞的组织定位和组成成分发生广泛改变,从而导致免疫系统失调,之后引发的组织损伤和缓慢愈合,导致了BPH发生和进展。本文通过总结良性前列腺增生与前列腺慢性炎症的相关性的临床研究结果,前列腺免疫细胞在病理生理机制层面与前两者之间的内在联系,以及抗炎药物对BPH-LUTS的干预作用,以其为BPH-LUTS的药物研发提供参考。 相似文献
46.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
47.
48.
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population
下载免费PDF全文
![点击此处可从《Asian Pacific journal of cancer prevention》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Partha S RoyTomar NyoduMunlima HazarikaB J SaikiaC BhuyanAmit InamdarC W NyutheB BorthakurJ D Sharma 《Asian Pacific journal of cancer prevention》2019,20(4):1139-1145
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients. 相似文献
49.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献50.